NCT05530291 is a clinical trial of Non-interventional in Chronic Kidney Disease, sponsored by Astellas Pharma Global Development, Inc..

Who is sponsoring NCT05530291?

NCT05530291 is sponsored by Astellas Pharma Global Development, Inc..

What drugs are being tested in NCT05530291?

Interventions in NCT05530291: Non-interventional.

What condition does NCT05530291 study?

NCT05530291 studies Chronic Kidney Disease.

Is NCT05530291 still recruiting?

NCT05530291 is currently completed. Last updated 7 November 2024.

Last reviewed 2024-11-07 · How we verify

NCT05530291

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis

Completed Last updated 7 November 2024

What this trial tests

trial testing Non-interventional in Chronic Kidney Disease in 85,259 participants. Completed in 22 November 2022.

Timeline

18 November 2022

Primary endpoint
22 November 2022

22 November 2022

Quick facts

Lead sponsor	Astellas Pharma Global Development, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	85,259
Start date	18 November 2022
Primary completion	22 November 2022
Estimated completion	22 November 2022
Sites	1 location across Germany

Drugs / interventions tested

Non-interventional

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →

Sponsor

Astellas Pharma Global Development, Inc. — full company profile →

Who can join

18 and older, any sex, with Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study consists of two phases. The purpose of phase 1 is to identify incidence and patterns of erythropoiesis-stimulating agent (ESA) hyporesponsiveness and its associated factors in ESA treated patients. The purpose of phase 2 to identify outcomes associated with ESA hyporesponsiveness. Key aspects of the phase 2 study design will entirely depend on the results from phase 1.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study.
Atzinger C, Arens HJ, Neri L, Arkossy O, et al · · 2025 · cited 1× · PMID 39581908 · DOI 10.1007/s12325-024-03015-4

Verify or expand the search:

Other trials of Non-interventional

Trials testing the same drug.

NCT06798298 — A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells · recruiting
NCT06746883 — A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacte · recruiting
NCT06622798 — Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients · recruiting
NCT06784154 — The Role of Ectopic Fat and Heart Attack Risk in HIV · recruiting
NCT06277037 — Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) · recruiting

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Other Astellas Pharma Global Development, Inc. trials

Trials by the same sponsor.

NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07475806 — A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep · Phase 2 · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07287995 — A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05530291 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Global Development, Inc.
Last refreshed: 7 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05530291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing